Standard usage and dosage specifications of Entacapone/Kedan

Entacapone (Entacapone) is a peripheral COMT inhibitor used for patients with Parkinson's disease, especially those with "on-off phenomenon" or significant fluctuations in levodopa plasma levels. In clinical applications, entacapone is designed as an oral tablet and must be used in combination with levodopa to maximize its efficacy. Standard usage is to take 1 tablet each time with levodopa/carbidopa or levodopa/benserazide, and use it as needed every day, usually corresponding to each dose of levodopa. With this combined administration, plasma concentrations of levodopa are prolonged and dopamine levels in the brain remain more constant, thereby improving the patient's motor symptoms.

The maximum recommended dose is 200mg each timeThe total daily dose should not exceed 2000mg, which usually corresponds to a maximum of 10 combined doses per day. The guidelines recommend that patients should strictly follow the doctor's instructions and should not increase the single or total daily dose at will to prevent liver function damage, blood pressure fluctuations or other adverse reactions caused by drug overdose. In clinical practice, doctors usually adjust the frequency of combined use of entacapone based on the patient's levodopa dosage, symptom fluctuations, and liver and kidney function status to achieve the best balance between drug effects and symptom management.

When administered, entacapone should be taken simultaneously with levodopa, not too early or too late. Because its mechanism of action relies on prolonging the existence time of levodopa in the periphery, if the time is misaligned, drug plasma concentration fluctuations may be exacerbated and clinical symptom control may be unstable. In addition, patients should maintain a regular schedule while taking the drug to avoid affecting drug absorption due to diet or other drugs. Some studies have pointed out that regular medication combined with lifestyle adjustments can significantly improve the "on-off phenomenon" and improve the stability of motor symptoms.

Reference materials:https://www.drugs.com/mtm/comtan.html